Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages

Patent metadata

Field	Value
Publication number	US-2020297749-A1
Application number	US-202016835978-A
Country	US
Kind code	A1
Filing date	Mar 31, 2020
Priority date	May 20, 2015
Publication date	Sep 24, 2020
Grant date	—

Abstract

The present invention relates to methods and pharmaceutical composition for modulation polarization and activation of macrophages. In particular, the present invention relates to methods for modulating macrophage M1/M2 polarization in a subject in need thereof comprising administering to the subject a therapeutically effective amount of P2Y2 receptor agonists or antagonists.

First claim

1 .- 15 . (canceled)

16 . A method of reducing macrophage M1 polarization in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a P2Y2 receptor agonist.

17 . A method according to claim 16 , wherein said administering reduces the secretion of an inflammatory cytokine selected from the group consisting of IL-6, IL-23, and IL-1beta by macrophages.

18 . A method according to claim 16 , wherein the subject is suffering from conditions associated with undesirable M1 polarization, and wherein said administering increases M2 macrophages pool in the subject.

19 . A method according to claim 16 , for treating an inflammatory disease in a subject in need thereof.

20 . A method according to claim 16 , for treating an auto-immune disease in a subject in need thereof.

21 . A method for promoting secretion of an inflammatory cytokine selected from the group consisting of IL-1beta, TNF, IL-12, and IL-23 by macrophage in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an inhibitor of P2Y2 receptor activity or expression.

22 . A method according to claim 21 , for treating an infectious disease in a subject in need thereof.

23 . A method according to claim 21 , for treating a viral infection, a bacterial infection, or a fungal infection.

24 . A method according to claim 21 , for reducing macrophage M2 polarization in a subject in need thereof.

25 . A method according to claim 21 , for treating a condition associated with undesirable M2 macrophage polarization.

26 . A method according to claim 21 , wherein said subject suffers from a condition associated with undesirable M2 macrophage polarization, said condition being selected from the group consisting of cancer, especially metastatic cancer, progressive fibrotic diseases such as for example idiopathic pulmonary fibrosis (IPF), hepatic fibrosis systemic sclerosis, allergy and asthma, atherosclerosis and Alzheimer's disease.

27 . A method according to claim 21 , wherein said subject suffers from a cancer selected from the group consisting of cancer cells from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal tract, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus; neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous; adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; Paget's disease, mammary; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma w/squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant; and roblastoma, malignant; Sertoli cell carcinoma; Leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extra-mammary paraganglioma, malignant; pheochromocytoma; glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malignant melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; brenner tumor, malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; struma ovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; kaposi's sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma; odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant; ameloblastic fibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor, meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant lymphoma; Hodgkin's disease; Hodgkin's lymphoma; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other specified non-Hodgkin's lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; hairy cell leukemia; metastatic cancer to bone, wherein the metastatic cancer is breast, lung, renal, multiple myeloma, thyroid, prostate, adenocarcinoma, blood cell malignancies, including leukemia and lymphoma; head and neck cancers; gastrointestinal cancers, including esophageal cancer, stomach cancer, colon cancer, intestinal cancer, colorectal cancer, rectal cancer, pancreatic cancer, liver cancer, cancer of the bile duct or gall bladder; malignancies of the female genital tract, including ovarian carcinoma, uterine endometrial cancers, vaginal cancer, and cervical cancer; bladder cancer; brain cancer, including neuroblastoma; sarcoma, osteosarcoma; and skin cancer, including malignant melanoma or squamous cell cancer.

28 . A method for promoting secretion of an inflammatory cytokine selected from the group consisting of IL-1beta, TNF, IL-12, and IL-23 by macrophages, comprising contacting said macrophages in vitro with an inhibitor of P2Y2 receptor activity or expression.

29 . A method according to claim 28 , wherein said macrophages have been obtained from a subject suffering from cancer.

30 . A method according to claim 28 , wherein said inhibitor is a small organic molecule, such as diphosphoric 5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)pentylphosphonic anhydride or 4-phenyl-amino-4-(2-methoxyphenyl)-2-sulfoanthraquinone.

31 . A method according to

Assignees

• Inst Nat Sante Rech Med
• Univ Paris Sud
• Roussy Inst Gustave
• Pasteur Institut
• Univ Pierre Et Marie Curie Paris 6
• Instituto Naz Per Le Malattie Infettive Irccs Lazzaro Spallanzani
• Univ Paris Diderot Paris 7
• Univ Paris Descartes
• Hopitaux Paris Assist Publique

Inventors

• Perfettini Jean-Luc
• Paoletti Audrey
• Gougeon Marie-Lise
• Kroemer Guido
• Piacentini Mauro

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K38/177

  Receptors; Cell surface antigens; Cell surface determinants · CPC title

• A61K31/7034

  attached to a carbocyclic compound, e.g. phloridzin · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K31/7084

  Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide · CPC title